Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, MexicoSARS-COV-2 우려 변동의 유병률 및 멕시코 몬테레이에있는 병원에서 COVID-19 획기적인 감염에 대한 관심의 변형Observational Study Published on 2022-01-142022-09-10 Journal: Viruses [Category] SARS, 변종, 임상, 치료기술, [키워드] Administered ambulatory patient ambulatory patients AstraZeneca B.1.617.2 B.1.621 Breakthrough infection breakthrough infections CanSino case-control study Complete concern control group COVID-19 COVID-19 vaccines defined Delta Efficacy first dose hospital Hospitalization Hospitalized hospitalized patient hospitalized patients immunization increased risk inoculation interest Latin America Local Mexico mild COVID-19 symptom mild COVID-19 symptoms Mu occurred Patient patients Pfizer/BioNTech Prevalence public health SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants second dose Sinovac Surveillance therapy vaccination Vaccine vaccine administration vaccine breakthrough infection vaccine breakthrough infections Vaccines variant of concern VoC VOCs VOIs was performed whole-genome sequencing [DOI] 10.3390/v14010154 PMC 바로가기 [Article Type] Observational Study
Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional StudyArticle Published on 2022-01-072022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI acceptance age antibody Associated factors belief benefit booster Characteristics China Chinese collected conducted country COVID-19 COVID-19 infection COVID-19 susceptibility COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines cross-sectional declining distribution dose Factor General population Health help individual information initial International Intervention knowledge knowledge score less multivariable logistic regression Participants provided receive Sinovac susceptibility the vaccine third dose vaccination Vaccine Vaccines variant were used [DOI] 10.3390/vaccines10010089 PMC 바로가기 [Article Type] Article
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study칠레에서 CoronaVac 및 BNT162b2 COVID-19 백신 출시 후 동적 IgG 혈청 양성: 감시 감시 연구Article Published on 2022-01-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 진단, 치료기술, [키워드] 95% CI absence Abstract age Analysis anti-SARS-CoV-2 IgG BNT162b2 BNT162b2 vaccine chronic disease collected Comorbidities CoronaVac COVID-19 COVID-19 vaccine declined diabete dose dynamic Effectiveness enrolled Final Finger prick first dose Gender had no hotspot IgG IgG test inactivated individual individuals Lateral flow test majority material men mRNA BNT162b2 vaccine National Older participant PCR Pfizer-BioNTech positive Prolonged proportion questionnaire ranged real-world data recall recipient recipients Regression respond SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 vaccine second dose significantly lower Sinovac Sociodemographic characteristics Spanish Surveillance tested translation vaccinated individual vaccination Vaccination strategies Vaccine Vaccines variable were excluded women [DOI] 10.1016/S1473-3099(21)00479-5 PMC 바로가기 [Article Type] Article
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving ImmunosuppressantsMedicine Published on 2021-12-082022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] acute respiratory syndrome anti-SARS-CoV-2 IgG antibody autoimmune conditions autoimmune skin diseases Beijing benefit booster doses calculated Cancer case-control study condition CoronaVac coronavirus coronavirus disease COVID-19 COVID-19 infection greater humoral immune response IgG IgG antibody Immune-mediated immunogenicity Immunosuppressant Immunosuppressed Immunosuppression immunosuppressive therapies immunosuppressive therapy Inactivated COVID-19 vaccine Infection lack methotrexate neutralizing antibody participant Patient patients patients with HIV percentage positive Prednisolone receiving reduction respond poorly response SARS-CoV-2 seroconversion rate serum Sinovac Sinovac Life Sciences statistical significance study participant subject subset the vaccine therapy vaccination Vaccine vaccine dose were used [DOI] 10.3389/fmed.2021.769845 PMC 바로가기 [Article Type] Medicine
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children실수로 예방 접종을 받은 건강한 어린이에서 비활성화된 SARS-CoV-2 백신(CoronaVac)의 안전성 및 면역원성Article Published on 2021-12-062022-09-12 Journal: Revista do Instituto de Medicina Tropical de São [Category] MERS, SARS, 진단, [키워드] ACE2 receptor binding adverse effects adverse event age Antibody titer binding Brazil children China collected contribute CoronaVac COVID-19 vaccine domain dose Follow-up healthy children IgG immunogenic inactivated increase in Local Mild positive positive serology presenting Protein robust Safe Safety SARS-COV-2 infection SARS-CoV-2 S1 SARS-CoV-2 vaccine serological response serology seronegative serum sample Seven Sinovac state Symptom tested vaccination Vaccine [DOI] 10.1590/S1678-9946202163083 PMC 바로가기 [Article Type] Article
The role of COVID-19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical-year medical students in Indonesia인도네시아에서 임상연도 의대생을 대상으로 Sinovac 백신 투여 후 1, 2, 3개월 후 항체가 중화를 위한 COVID-19 생존자 상태 및 성별의 역할Article Published on 2021-12-012022-09-12 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome administration analyzed antibody Antibody titers antibody titers. collected conducted coronavirus COVID-19 COVID-19 vaccine cross-sectional database demographics distribution Effect female gender Gender individual Indonesia males Mann-Whitney U test neutralizing antibody Neutralizing antibody titer participant positive positive RT-PCR Quantitative retrieved SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RT-PCR test serology significantly higher Sinovac Sinovac vaccine survivor t-test vaccination Vaccine vaccine administration variable Village [DOI] 10.1016/j.ijid.2021.10.009 PMC 바로가기 [Article Type] Article
Herpetic Keratitis Preceded by COVID-19 VaccinationCase Report Published on 2021-11-252022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] accelerated Antiviral caused clinician Corneal COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Endotheliitis herpes simplex keratitis herpetic keratitis inactivated Inactivated vaccine keratitis latency occurred ocular pandemic Patient Penetrating receiving reported risk scarring Sinovac suggested the vaccine treated triggering Vaccine development virus [DOI] 10.3390/vaccines9121394 PMC 바로가기 [Article Type] Case Report
Development of an Inactivated Vaccine against SARS CoV-2SARS COV-2에 대한 불활성 백신의 개발Article Published on 2021-11-022022-09-10 Journal: Vaccines [Category] 비임상, [키워드] Adenovirus Aluminium aluminium hydroxide animal models approved AstraZeneca BALB/c mice breath candidate candidate vaccine changed clinical development clinical trial Complete COVID-19 COVID-19 pandemic COVID-19 vaccine develop development Device distribution Efficacy elicited Emergency use ERUCoV-VAC ferrets hACE2 HCoV help human clinical trial human clinical trials hydroxide immunogenic immunogenicity inactivated Inactivated vaccine include Johnson & Johnson K18-hACE2 Medical devices Medicine mice Moderna mRNA name outbreak Pfizer-BioNTech Phase 3 phase 3 clinical trial progression Protective respiratory safety evaluation SARS CoV-2 SARS-CoV-2 SARS-CoV-2 vaccine Sinopharm Sinovac Spread strain strong immune response the vaccine the WHO transgenic mice TURKOVAC university upper respiratory tract upper respiratory tracts Vaccine vaccine candidate Vaccines Viral viral clearance rate Viral vector viral vectors was used [DOI] 10.3390/vaccines9111266 PMC 바로가기 [Article Type] Article
COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient DosesArticle Published on 2021-10-282022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] ANOVA barriers Chi-square Chinese choice city compulsory vaccination conducted COVID-19 COVID-19 vaccination COVID-19 vaccine death Descriptive analysis doses examined expressed Factors Free General population group Health Hesitancy highest Incentives Intention measure professional promote random receive receiving Serious Adverse Event Sinovac subject vaccination Vaccine vaccine choice vaccine dose Vaccine hesitancy variety [DOI] 10.3390/vaccines9111250 PMC 바로가기 [Article Type] Article
COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, IndonesiaResearch Published on 2021-10-122022-10-28 Journal: BMC Pharmacology & Toxicology [Category] COVID-19, [키워드] Adverse adverse event AEFI booster dose caused concern conducted Corona Vaccines CoronaVac correlated COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional determine Dysphagia Emergency Fever first dose Follow-up Gender headache Health care immunization immunologic response Indonesia injection malaise Mild symptom nausea not correlated novel occur Other Pain patients PHEIC Post-vaccination Prevent Public questionnaire receive reported respiratory Result SARS-CoV-2 SARS-CoV-2 vaccination Sinovac student supplementary material Symptom the vaccine vaccination Vaccine was used WHO World Health Organization [DOI] 10.1186/s40360-021-00528-4 PMC 바로가기 [Article Type] Research